川芎嗪对肺间质纤维化患者运动心肺功能改善的研究

The effect of ligustrazin on exercise tolerance of patients with pulmonary fibrosis

目的观察川芎嗪对肺间质纤维化患者的临床表现、运动心肺功能及血气的改善情况。方法 60例肺间质纤维化患者随机分为两组,治疗组予以川芎嗪注射液治疗,对照组予口服强的松;两组均治疗2个月后观察疗效。结果治疗2个月后显示治疗组肺功能、血气及运动心肺功能指标(Wmax、V02max/kg、VO2/HR、VEmax)均较治疗前改善(P<0.05);与对照组比较亦有改善(P<0.05)。结论川芎嗪注射液能显著改善肺间质纤维化病人的运动心肺功能和生活质量。

[ Objective ] By performing the cardiopulmonary exercise testing in patients with pulmonary fibrosis treated by ligustrazin, to explore the effective methods to improve the exercise capacity and life quality of patients with pulmonary fibrosis. [Methods] 60 patients with pulmonary fibrosis were divided into 2 groups： ligustrazin group and hydroeortisone group. Treatment lasted 2 months. [Result] After 2 months,not only lung function and blood gas were evidently raised （P 〈0.05）, but also the maximal work, V02max/kg, V02/HR, VEmax were obviously improved （P 〈0.05） in ligustrazin group. [ Conclusion ] Ligustrazin can improve the exercise cardiopulmonary capacity and life quality of patients with pulmonary fibrosis.